Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: A randomised, controlled, double-masked clinical trial

British Journal of Ophthalmology

Volumn 91, Issue 5, 2007, Pages 667-672

  Cochereau, Isabelle ^a   Goldschmidt, Pablo ^b   Goepogui, André ^c   Afghani, Tayyab ^d   Delval, Laurent ^e   Pouliquen, Pascale ^e   Bourcier, Tristan ^f   Robert, Pierre Yves ^g  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b Laboratoire   (France)

^c centre hospitalier et universitaire de Conakry   (Guinea)

^d AL SHIFA TRUST EYE HOSPITAL   (Pakistan)

^e Laboratoires Thea   (France)

^f Hopital des XV XX   (France)

^g DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; AZYTER; PLACEBO; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ARTICLE; CHILD; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TRACHOMA; TREATMENT DURATION; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; OPHTHALMIC SOLUTIONS; TRACHOMA; TREATMENT OUTCOME;

EID: 34248215088     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.099275     Document Type: Article

References (37)

1. Dandona R, Dandona L. Socioeconomic status and blindness. Br J Ophthalmol 2001;85:1484-8.
2. Dawson CR, Jones BR, Tarizzo ML. Guide to trachoma control in programmes for the prevention of blindness. 1981:1-58.
3. Mabey D, Bailey R. Eradication of trachoma worldwide. Br J Ophthalmol 1999;83:1261-3.
4. Mabey D, Fraser-Hurt N. Trachoma. BMJ 2001;323:218- 21.
5. Tabbara KF. Blinding trachoma: the forgotten problem. Br J Ophthalmol 2001;85:1397-9.
6. Tabbara KF. Trachoma: a review. J Chemother 2001;13:18-22.
7. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51.
8. Dawson CR, Daghfous T, Hoshiwara I, et al. Trachoma therapy with topical tetracycline and oral erythromycin: a comparative trial. Bull World Health Organ 1982;60:347-55.
9. World Health Organisation and Programme for the Prevention of Blindness Primary health care level management of trachoma. 1993;WHO/PBL/, 93:33, 1-42.
10. World Health Organisation. Report of the First Meeting of the WHO Alliance for the Global Elimination of Trachoma. Geneva, Switzerland, 30 june-1 July 1997. 1997;WHO/PBL/GET/, 97:1, 1-33.
11. Dawson CR, Daghfous T, Whitcher J, et al. Intermittent trachoma chemotherapy: a controlled trial of topical tetracycline or erythromycin. Bull World Health Organ 1981;59:91-7.
12. Bailey RL, Arullendran P, Whittle HC, et al. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993;342:453-6.
13. Bowman RJ, Sillah A, Van Dehn C, et al. Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. Invest Ophthalmol Vis Sci 2000;41:4074-9.
14. Tabbara KF, Abu-el-Asrar A, al-Omar O, et al. Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology 1996;103:842-6.
15. Chern KC, Shrestha SK, Cevallos V, et al. Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. Br J Ophthalmol 1999;83:1332-5.
16. World Health Organisation. Report of the Third Meeting of the WHO Alliance for the Global Elimination of Trachoma. Ouarzazate, Morocco: 19-20 October 1998, 1999;WHO/PBD/GET/, 99:3, 1-58.
17. Geopogui A, Huguet P, Mariotti S, et al. Trachome en Guinée (Conakry) : résultats d'une enquête épidémiologique en Haute Guinée. Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique, 2000;77, 78, 79:151-63.
18. The European Agency for the Evaluation of Medicinal Products (EMEA). Committee for Proprietary Medicinal Products (CPMP). Note for guidance on clinical investigation of medicinal products in children. 1997:1-11.
19. The European Agency for the Evaluation of Medicinal Products (EMEA) Committee for Proprietary Medicinal Products (CPMP). ICH topic E11: Clinical investigation of medicinal products in the paediatric population, Note for guidance on clinical investigation of medicinal products in the paediatric population., 2000:1-12.
20. The European Agency for the Evaluation of Medicinal Products (EMEA). Committee for Proprietary Medicinal Products (CPMP). Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections. 2004:1-22.
21. Thylefors B, Dawson CR, Jones BR, et al. A simple system for the assessment of trachoma and its complications. Bull World Health Organ 1987;65:477-83.
22. Frick KD, West SK. The SAFE strategy for trachoma control: planning a cost-effectiveness analysis of the antibiotic component and beyond. Ophthalmic Epidemiol 2001;8:205-14.
23. D'Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med 2003;22:169-86.
24. File TM Jr, Schlemmer B, Garau J, et al. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother 2001;48:67-74.
25. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002;46:1746-54.
26. Shlaes DM, Moellering RC Jr. The United States Food and Drug Administration and the end of antibiotics. Clin Infect Dis 2002;34:420-2.
27. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999;44:501-13.
28. Dawson CR, Schachter J, Sallam S, et al. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin Infect Dis 1997;24:363-8.
29. Guzey M, Aslan G, Ozardali I, et al. Three-day course of oral azithromycin vs topical oxytetracycline/polymyxin in treatment of active endemic trachoma. Jpn J Ophthalmol 2000;44:387-91.
30. Nouri MT, Soukehal A. Traitement du trachome évolutif en milieu scolaire dans le sud algérien. Résultats d'un essai thérapeutique contrôlé comparatif entre azithromycine per os et oxytétracycline pommade. Rev Int Trach Pathol Ocul Trap Subtrop Sante Publique, 2000;77, 78, 79:165-84.
31. Chidambaram JD, Melese M, Alemayehu W, et al. Mass antibiotic treatment and community protection in trachoma control programs. Clin Infect Dis 2004;39:e95-e97.
32. Fraser-Hurt N, Bailey RL, Cousens S, et al. Efficacy of oral azithromycin versus topical tetracycline in mass treatment of endemic trachoma. Bull World Health Organ 2001;79:632-40.
33. Holm SO, Jha HC, Bhatta RC, et al. Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull World Health Organ 2001;79:194-200.
34. Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet 1999;354:630-5.
35. Solomon AW, Holland MJ, Alexander ND, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 2004;351:1962-71.
36. West ES, Munoz B, Mkocha H, et al. Mass Treatment and the Effect on the Load of Chlamydia trachomatis Infection in a Trachoma-Hyperendemic Community. Invest Ophthalmol Vis Sci 2005;46:83-7.
37. Ejere H, Alhassan MB, Rabiu M. Face washing promotion for preventing active trachoma. Cochrane Database Syst Rev 2004;3:CD003659.